Lithuania vs Oman: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Lithuania
0.1%
in 2024
Oman
0.1%
in 2024
Lithuania rank
112th
Oman rank
112th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Lithuania
- Oman
How they compare
Lithuania currently reports 0.1% against 0.1% in Oman, a difference of 0.0%.
Across all 10 years both countries report, Oman has been ahead every year.
Lithuania ranks 112th and Oman ranks 112th of 215 countries.
Head to head by decade
| Decade | Lithuania | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.1% | 0.1% | 0.0% | — |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Lithuania or Oman?
- Lithuania, at 0.1% against 0.1% in Oman as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Lithuania and Oman?
- 0.0%, with Lithuania ahead.
- How many years of comparable data are there for Lithuania and Oman?
- 10 years are reported by both, from 2015 to 2024.
- How do Lithuania and Oman rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Lithuania ranks 112th and Oman ranks 112th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.